PLX Gets Boost as EU Review Backs Less Frequent Dosing for Elfabrio—Potential Game-Changer for Fabry Patients

Regulatory Momentum: CHMP Positive Opinion Opens Door for Reduced Treatment Burden

Protalix BioTherapeutics (NYSE: PLX) shares were active today following news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency granted a positive opinion on an additional, less frequent dosing regimen for Elfabrio (pegunigalsidase alfa). If authorized by the European Commission, adult Fabry disease patients stable on enzyme replacement therapy could receive 2mg/kg infusions every four weeks, rather than every two. The formal EC decision is anticipated by March 2026.

Patient Impact: Once-Monthly Dosage May Significantly Improve Quality of Life

This revised regimen—pending regulatory approval—would mean fewer hospital or home infusions, directly addressing the desire of many Fabry patients to reduce treatment disruptions to their daily lives. "Extending the time between infusions means people living with Fabry disease can focus on what truly matters, living their lives," said Giacomo Chiesi, EVP at Chiesi Global Rare Diseases.

Market and Financial Implications: $25M Milestone Payment Awaits Approval

The CHMP recommendation follows comprehensive studies, including the BRIGHT switch-over and ongoing extension studies, which assessed efficacy, safety, and pharmacokinetics over up to five years. If granted final approval, Protalix is set to receive a $25 million milestone payment from Chiesi—an important catalyst for the biotech’s development pipeline. The change could also strengthen Elfabrio's competitive positioning in Europe’s rare disease market.

Looking Ahead: What’s Next for Protalix and Fabry Therapy Innovation?

The step toward once-monthly dosing could ripple through the ecosystem of rare disease therapies, reinforcing Protalix’s emerging role as an innovator. The company’s proprietary ProCellEx® platform and strategic alliances with Chiesi and Pfizer continue to underpin their push for more accessible and sustainable treatments. With the EC decision still pending, both investors and patients will be following closely in anticipation.

Takeaway: Regulatory Momentum Highlights Patient-Centered Focus

While regulatory approval is not guaranteed, the CHMP’s positive opinion validates years of investment and research in making Fabry disease treatment more manageable. Patients may soon see meaningful improvements in convenience and quality of life, and PLX could benefit from renewed commercial momentum in the rare disease therapy landscape. The months ahead will reveal whether Elfabrio’s new dosing schedule becomes the new standard in Fabry care across Europe.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI